FDA Deputizes Doctors In Hunt For "Bad Ads"
This article was originally published in The Pink Sheet Daily
Outreach program, which asks for tips on worrisome promotional behavior, might be an effective deterrent even without finding many violations.
You may also be interested in...
The agency continues to publicize the program for health care professionals and the public to report misleading drug promotion.
Mylan direct-to-consumer ad misleadingly suggested that as long as allergy sufferers have the product with them, they don’t need to do anything else to avoid anaphylactic shock, FDA says.
In its first year of operation, FDA's "Bad Ad" program succeeded in more than tripling the number of complaints the agency receives about deceptive drug advertising, and now the agency is assessing how best to expand upon the success of the initiative.